STOCK TITAN

Ngm Biopharmaceuticals - NGM STOCK NEWS

Welcome to our dedicated page for Ngm Biopharmaceuticals news (Ticker: NGM), a resource for investors and traders seeking the latest updates and insights on Ngm Biopharmaceuticals stock.

NGM Biopharmaceuticals (NGM) is a clinical-stage biopharmaceutical company pioneering novel biologic therapies through its integrated drug discovery platform. This page serves as the definitive source for verified updates on the company's research advancements, clinical developments, and strategic milestones.

Investors and industry professionals will find timely updates across key areas including clinical trial progress, regulatory filings, partnership announcements, and financial reporting. Our curated collection ensures access to primary-source materials while maintaining compliance with financial disclosure standards.

The news archive features categorized updates on therapeutic developments in NGM's core focus domains: cardio-metabolic disorders, liver diseases, and emerging oncology programs. Each entry connects to the company's biology-driven approach, emphasizing its protein engineering capabilities and target validation methodologies.

For consistent monitoring of NGM's innovative pipeline, bookmark this page or check back regularly. Subscribers to our financial updates service receive automated alerts when new material disclosures are published.

Rhea-AI Summary
NGM Biopharmaceuticals, Inc. has been acquired by Atlas Neon Parent, Inc., an affiliate of The Column Group, LP, through a successful cash tender offer at $1.55 per share. The acquisition resulted in NGM Bio becoming a privately held subsidiary of Parent.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary
NGM Biopharmaceuticals announces presentation of NGM707 clinical data at AACR Annual Meeting
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.64%
Tags
conferences clinical trial
-
Rhea-AI Summary
NGM Biopharmaceuticals, Inc. provided updates on ongoing trials for NGM707 in colorectal cancer, NGM120 for hyperemesis gravidarum, and aldafermin for primary sclerosing cholangitis. The company reported $144.2 million in cash and announced a merger agreement with Atlas Neon Parent, Inc. Key financial results for the fourth quarter and full year 2023 were also disclosed.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
Rhea-AI Summary
NGM Bio announced a definitive Agreement and Plan of Merger with Atlas Neon Parent, Inc. and Atlas Neon Merger Sub, offering $1.55 per share in cash, an 80% premium over the closing share price. The acquisition, valued at $135 million, involves a cash tender offer for all outstanding shares not held by affiliates of The Column Group, LP. The transaction is recommended by a Special Committee of independent directors and is expected to close in the second quarter of 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-20.16%
Tags
-
Rhea-AI Summary
NGM Biopharmaceuticals, Inc. announced CEO David J. Woodhouse will participate in a panel on oncology targets at the Cowen 44th Annual Health Care Conference. The event will be webcast live and available for replay on NGM Bio's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
19.25%
Tags
conferences
-
Rhea-AI Summary
NGM Biopharmaceuticals, Inc. (Nasdaq: NGM) announced CEO and CFO participation in the B. Riley Securities 4th Annual Oncology Conference. They will provide a business update on NGM Bio’s oncology portfolio. The presentation will be available for replay on NGM Bio’s website for at least 30 days.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.75%
Tags
conferences
Rhea-AI Summary
NGM Biopharmaceuticals, Inc. (NGM Bio) (Nasdaq: NGM) announces encouraging findings in heavily pretreated patients in multiple solid tumor indications, including MSS colorectal cancer (CRC), in ongoing Phase 1 Part 1b study evaluating NGM707, a dual ILT2/ILT4 antagonist antibody, in combination with KEYTRUDA® (pembrolizumab) and outlines its strategy to evolve clinical development of its product candidates aldafermin and NGM120 to focus on rare conditions.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.4%
Tags
-
Rhea-AI Summary
NGM Biopharmaceuticals, Inc. (NGM Bio) (Nasdaq: NGM) shared positive results from its Phase 2b ALPINE 4 trial of aldafermin, an engineered FGF19 analog product candidate, in patients with compensated cirrhosis due to NASH. The trial met its primary endpoint, showing a statistically significant reduction in Enhanced Liver Fibrosis (ELF) score compared to placebo after 48 weeks of treatment. Dose-dependent improvements were reported across histologic and non-invasive secondary endpoints. The study also demonstrated that aldafermin treatment up to one year was generally well tolerated with no treatment-related serious adverse events.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.44%
Tags
-
Rhea-AI Summary
NGM Biopharmaceuticals, Inc. (NGM Bio) (Nasdaq: NGM) Announces CEO Participation in Evercore ISI HealthCONx Conference and Jefferies London Healthcare Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.34%
Tags
conferences
Rhea-AI Summary
NGM Biopharmaceuticals reports $166.0 million in cash as of September 30, 2023, with expected cash runway into mid-2025. Jean-Frédéric Viret appointed as CFO. Progress made on myeloid checkpoint solid tumor programs. Data from Phase 2b trial of aldafermin selected for oral presentation at AASLD The Liver Meeting.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5%
Tags
Ngm Biopharmaceuticals

Nasdaq:NGM

NGM Rankings

NGM Stock Data

128.53M
64.29M
21.08%
54.16%
2.01%
Biotechnology
Healthcare
Link
United States
South San Francisco